Turk Ilac Ve Serum Sanayi Anonim Sirketi Past Earnings Performance
Past criteria checks 1/6
Turk Ilac Ve Serum Sanayi Anonim Sirketi has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 47.1% per year. Turk Ilac Ve Serum Sanayi Anonim Sirketi's return on equity is 1.3%, and it has net margins of 1.1%.
Key information
6.8%
Earnings growth rate
2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 47.1% |
| Return on equity | 1.3% |
| Net Margin | 1.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Turk Ilac Ve Serum Sanayi Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,638 | 18 | 166 | 0 |
| 31 Dec 23 | 1,913 | 106 | 159 | 0 |
| 30 Sep 23 | 1,207 | 91 | 89 | 0 |
| 30 Jun 23 | 991 | 58 | 85 | 0 |
| 31 Mar 23 | 1,033 | 67 | 87 | 0 |
| 31 Dec 22 | 1,637 | -82 | 171 | 0 |
| 30 Sep 22 | 825 | 31 | 94 | 0 |
| 30 Jun 22 | 812 | 13 | 72 | 0 |
| 31 Mar 22 | 760 | 37 | 58 | 0 |
| 31 Dec 21 | 673 | 37 | 40 | 0 |
| 30 Sep 21 | 554 | 65 | 37 | 0 |
| 30 Jun 21 | 426 | 86 | 35 | 0 |
| 31 Mar 21 | 218 | 51 | 27 | 0 |
| 31 Dec 20 | 200 | 33 | 27 | 0 |
| 30 Sep 20 | 219 | 52 | 26 | 0 |
| 31 Dec 19 | 152 | 13 | 21 | 0 |
| 31 Dec 18 | 97 | 14 | 13 | 0 |
| 31 Dec 17 | 53 | 8 | 11 | 0 |
Quality Earnings: TRILC has a high level of non-cash earnings.
Growing Profit Margin: TRILC's current net profit margins (1.1%) are lower than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRILC's earnings have grown by 6.8% per year over the past 5 years.
Accelerating Growth: TRILC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TRILC had negative earnings growth (-72.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.4%).
Return on Equity
High ROE: TRILC's Return on Equity (1.3%) is considered low.